Online Only Articles

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;Department of Epidemiology, University of Washington, Seattle, WA, USA
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
Stanford University, CA, USA
Jazz Pharmaceuticals, Ewing, NJ, USA
Jazz Pharmaceuticals, Ewing, NJ, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
Vol. 103 No. 3 (2018): March, 2018 https://doi.org/10.3324/haematol.2017.182642